Julian D Gillmore
Overview
Explore the profile of Julian D Gillmore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
273
Citations
9305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al.
J Am Coll Cardiol
. 2024 Jun;
83(24):2411-2422.
PMID: 38866445
Background: Transthyretin cardiomyopathy (ATTR-CM) was an exclusion criterion in randomized clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Objectives: This study sought to assess the effectiveness and tolerability of SGLT2i...
22.
Chiaro G, Stancanelli C, Koay S, Vichayanrat E, Sander L, Ingle G, et al.
Clin Auton Res
. 2024 May;
34(3):341-352.
PMID: 38769233
Background: The cardiomyopathic and neuropathic phenotype of hereditary transthyretin amyloidosis are well recognized. Cardiovascular autonomic dysfunction is less systematically and objectively assessed. Methods: Autonomic and clinical features, quantitative cardiovascular autonomic...
23.
Ioannou A, Fumagalli C, Razvi Y, Porcari A, Rauf M, Martinez-Naharro A, et al.
J Am Coll Cardiol
. 2024 May;
84(1):43-58.
PMID: 38739065
Background: The 6-minute walk test (6MWT) represents a comprehensive functional assessment that is commonly used in patients with heart failure; however, data are lacking in patients with transthyretin cardiac amyloidosis...
24.
Gillmore J, Lystig T, Fox J
N Engl J Med
. 2024 Apr;
390(14):1346-1347.
PMID: 38598813
No abstract available.
25.
Ioannou A, Cappelli F, Emdin M, Nitsche C, Longhi S, Masri A, et al.
J Am Coll Cardiol
. 2024 Mar;
PMID: 38530684
Background: Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyopathy. The clinical course varies among individuals and there are no established measures to assess disease progression. Objectives: The goal of this...
26.
Patel R, Bandera F, Venneri L, Porcari A, Razvi Y, Ioannou A, et al.
JAMA Cardiol
. 2024 Mar;
9(4):367-376.
PMID: 38446436
Importance: Cardiopulmonary exercise testing (CPET) has an established role in the assessment of patients with heart failure. However, data are lacking in patients with transthyretin (ATTR) amyloidosis. Objective: To use...
27.
Verona G, Raimondi S, Canetti D, Mangione P, Marchese L, Corazza A, et al.
Protein Sci
. 2024 Feb;
33(3):e4931.
PMID: 38380705
The mechanism that converts native human transthyretin into amyloid fibrils in vivo is still a debated and controversial issue. Commonly, non-physiological conditions of pH, temperature, or organic solvents are used...
28.
Choy C, Steeds R, Pinney J, Baig S, Turvey-Haigh L, Wahid Y, et al.
Clin Med (Lond)
. 2024 Feb;
24(1):100004.
PMID: 38377730
There has been an exponential increase in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CA). In response, the Midlands Amyloidosis Service was launched with the aim of providing patients with a...
29.
Carroll A, Razvi Y, ODonnell L, Veleva E, Heslegrave A, Zetterberg H, et al.
Amyloid
. 2024 Feb;
31(2):95-104.
PMID: 38348665
Background: Neurofilament light chain (NfL) has emerged as a sensitive biomarker in hereditary transthyretin amyloid polyneuropathy (ATTRv-PN). We hypothesise that NfL can identify conversion of gene carriers to symptomatic disease,...
30.
Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C, et al.
Circulation
. 2024 Feb;
149(15):1157-1168.
PMID: 38328945
Background: The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM) might reflect cardiac amyloid burden and be associated with outcome....